NHS Circular: MSAN (2024) 57

Chief Medical Officer Directorate Pharmacy and Medicines Division



4 October 2024

# **Medicine Supply Alert Notice**

Isosorbide mononitrate 60mg modified-release tablets and capsules - Update

Priority: Level 2\*

Valid until: various re-supply dates, see below

#### Issue

- 1. Chemydur® 60XL tablets are out of stock until mid-October 2024.
- 2. Monomax® XL 60mg tablets are out of stock until early October 2024.
- 3. Monomil® XL 60mg tablets are in limited supply until late December 2024.
- 4. Nyzamac® SR 60mg capsules are out of stock until late October 2024.
- 5. Isotard<sup>®</sup> 60XL, Medomon<sup>®</sup> XL, Relosorb<sup>®</sup> XL and Tardisc<sup>®</sup> XL 60mg tablets remain available and can support the increased demand.
- 6. Other brands of isosorbide mononitrate 60mg modified-release tablets are available, however cannot support the increase in demand.
- 7. UK-wide Serious Shortage Protocols (SSPs) for Chemydur<sup>®</sup> 60XL, Monomax<sup>®</sup> XL and Monomil<sup>®</sup> XL 60mg tablets, and Nyzamac<sup>®</sup> SR 60mg capsules were issued on 06<sup>th</sup> of September 2024. See PCA(P)24, PCA(P)25, PCA(P)26 and PCA(P)27 for more information.

#### **Advice and Actions**

- 8. No new patients should be initiated on Chemydur® 60XL, Monomax® XL, Monomil® XL 60mg modified release tablets or Nyzamac® SR 60mg capsules until the supply issues have resolved.
- 9. Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should:
  - consider prescribing isosorbide mononitrate 60mg modified-release tablets generically, to enable any available brand to be dispensed, where appropriate; or
  - consider prescribing an available alternative brand of isosorbide mononitrate 60mg modified release tablet, and
  - consider patient history and previous hypersensitivity, or adverse reactions if prescribing an alternative brand.
- 10. Where a prescription for Chemydur<sup>®</sup> 60XL, Monomax<sup>®</sup> XL or Monomil<sup>®</sup> XL 60mg tablets, or Nyzamac<sup>®</sup> SR 60mg capsules is presented and cannot be fulfilled, pharmacists and dispensing doctors should:
  - supply an alternative isosorbide mononitrate 60mg modified-release tablet according to the products specified in SSP073 - SSP076;
  - ensure the cautions and exclusion criteria are taken into account when considering using an SSP;

<sup>\*</sup>https://www.nss.nhs.scot/media/1842/medicine-supply-alert-notices-definitions-of-classifications-21-october-2019.pdf

- ensure patients / carers are counselled regarding the substitute product; and
- if the patient is deemed ineligible or does not consent to receive an alternative product via the SSP, they should be promptly referred back to the prescriber.
- 11. Patient reassurance may be needed when switching between brands of isosorbide mononitrate modified release. Prescribers and pharmacy teams should counsel patients on the change and possible adverse events they may experience, particularly in the first few days, the most important being hypotension, tachycardia, and worsening headaches. If they have concerns, patients should be advised to contact their doctor.

#### Additional Information

12. Chemydur® 60XL, Monomax® XL, Monomil® XL 60mg MR tablets and Nyzamac® SR 60mg MR capsules are licensed for the prophylactic treatment of angina pectoris. They are administered once daily in the morning, up to a maximum dose of 120mg once daily. In new patients, the dose can be titrated to minimise the possibility of headache, by initiating the treatment with 30mg (half tablet), or with a lower dose capsule, for the first 2 - 4 days. For patients transitioning between brands, dose titration may also be required if they experience loss of efficacy or side effects after switching.

## Links to further information

- SmPC Monomil XL 60mg Tablets
- SmPC Chemydur 60XL Tablets
- SmPC Monomax XL 60 mg Tablets
- SmPC Nyzamac SR Capsules
- SmPC Isotard 60XL Tablets
- SmPC Relosorb XL Tablets
- SmPC Medomon XL 60mg Tablets
- SmPC Tardisc XL 60 Tablets
- BNF\_Isosorbide mononitrate
- NHSBSA Serious Shortage Protocols
- PCA(P)24 SSP: Isosorbide Mononirate (Chemydur® 60XL) modified release tablet
- PCA(P)25 SSP: Isosorbide Mononirate (Monomax® XL 60mg) modified release tablet
- PCA(P)26 SSP: Isosorbide Mononirate (Monomil® XL 60mg) modified release tablet
- PCA(P)27 SSP: Isosorbide Mononirate (Nyzamac<sup>®</sup> XL 60mg) modified release tablet

### Specialist Pharmacy Service (SPS) website

13. The UK Department of Health and Social Care (DHSC) in conjunction with SPS have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the <a href="SPS website">SPS website</a>. Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.

14. We encourage prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

## **Enquiries**

15. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to <a href="mailto:PharmacyTeam@gov.scot">PharmacyTeam@gov.scot</a> (primary care) or <a href="mailto:NSS.NHSSMedicineShortages@nhs.scot">NSS.NHSSMedicineShortages@nhs.scot</a> (secondary care).